Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial (2015)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- Subjects: NEOPLASIAS MAMÁRIAS (TERAPIA;COMPLICAÇÕES); QUIMIOTERAPIA (EFEITOS ADVERSOS); HIPERTENSÃO (ETIOLOGIA)
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2015
- Source:
- Título: Journal of Clinical Oncology
- ISSN: 0732-183X
- Volume/Número/Paginação/Ano: v. 33, n. 15S , abstr. 547, 2015
- Conference titles: ASCO Annual Meeting
-
ABNT
MACKEY, John Robert et al. Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/547?sid=fe5b0a84-c8e4-4c63-8084-facacd36f611. Acesso em: 24 jan. 2026. , 2015 -
APA
Mackey, J. R., Lipatov, O. N., Martin, M., Webster, M., Hegg, R., Verma, S., et al. (2015). Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/547?sid=fe5b0a84-c8e4-4c63-8084-facacd36f611 -
NLM
Mackey JR, Lipatov ON, Martin M, Webster M, Hegg R, Verma S, Vazquez MR, Fresco R, Thireau F, Houe V, Press MF, Narasimhan A, Damaraju S. Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial [Internet]. Journal of Clinical Oncology. 2015 ; 33( 15S ):[citado 2026 jan. 24 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/547?sid=fe5b0a84-c8e4-4c63-8084-facacd36f611 -
Vancouver
Mackey JR, Lipatov ON, Martin M, Webster M, Hegg R, Verma S, Vazquez MR, Fresco R, Thireau F, Houe V, Press MF, Narasimhan A, Damaraju S. Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial [Internet]. Journal of Clinical Oncology. 2015 ; 33( 15S ):[citado 2026 jan. 24 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/547?sid=fe5b0a84-c8e4-4c63-8084-facacd36f611 - Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial
- Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC)
- Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
- Hormonioterapia neoadjuvante no câncer de mama
- Superexpressao do oncogene her-2/neu em carcinomas de mama: analise clinica e imunohistoquimica
- Tratamento neoadjuvante no câncer de mama
- Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
- Terapia estrogenica e cancer de mama
- Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
